AEON Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA BPD Type 2b Meeting Request | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
ABP-450 Analytical Comparability Program Completion Quarterly95.0Target: 100% completion of analytical comparability program
Outstanding Debt Reduction Annually90.0Target: Maintain debt reduction above 90% post-Daewoong note exchange
Cash Runway (Months) Quarterly3.0Target: Secure additional financing to extend runway beyond Q3 2026
Watch Items
- FDA BPD Type 2b Meeting RequestTrigger: Submission of formal request to the FDA in 2H 2026Action: Prepare comprehensive analytical similarity package based on Type 2a feedback
- NYSE American Continued Listing ComplianceTrigger: Receipt of compliance notification from NYSE AmericanAction: Execute strategic plan to regain compliance; triggers vesting of CFO's performance-based RSUs (PSUs)
- Phase 3 Cervical Dystonia Trial InitiationTrigger: Finalization of trial protocol and regulatory clearanceAction: Initiate patient enrollment for the pivotal Phase 3 study of ABP-450
Research as of 20 Jun 2026